Journal
CANCER LETTERS
Volume 269, Issue 1, Pages 7-17Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.03.037
Keywords
historic deacetylase inhibitor; apoptosis; autophagy; bortezomib; TRAIL
Categories
Funding
- Institute for Drug Development, Cancer Therapy and Research Center at The Umversity of Texas Health Science Center at San Antonio
Ask authors/readers for more resources
Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs are a promising target for pharmacological inhibition. HDAC inhibitors can induce cell-cycle arrest, promote differentiation, and stimulate tumor cell death. These properties have prompted numerous preclinical and clinical investigations evaluating the potential efficacy of HDAC inhibitors for a variety of malignancies. The preferential toxicity of HDAC inhibitors in transformed cells and their ability to synergistically enhance the anticancer activity of many chemotherapeutic agents has further generated interest in this novel class of drugs. Here we summarize the different mechanisms of HDAC inhibitor-induced apoptosis and discuss their use in combination with other anticancer agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available